These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 28361189)

  • 21. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
    Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of calculation method on kidney dosimetry in
    Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
    Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosimetry and pharmacokinetics of [
    Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of
    Moraitis A; Jentzen W; Fragoso Costa P; Kersting D; Himmen S; Coelho M; Meckel M; van Echteld CJA; Fendler WP; Herrmann K; Sraieb M
    J Nucl Med; 2024 Jun; 65(6):931-937. PubMed ID: 38637142
    [No Abstract]   [Full Text] [Related]  

  • 26. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
    Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
    Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 29. Significant impact of transient deterioration of renal function on dosimetry in PRRT.
    Van Binnebeek S; Baete K; Terwinghe C; Vanbilloen B; Haustermans K; Mortelmans L; Borbath I; Van Cutsem E; Verslype C; Mottaghy FM; Verbruggen A; Deroose CM
    Ann Nucl Med; 2013 Jan; 27(1):74-7. PubMed ID: 22961123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
    Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
    Forrer F; Krenning EP; Kooij PP; Bernard BF; Konijnenberg M; Bakker WH; Teunissen JJ; de Jong M; van Lom K; de Herder WW; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1138-46. PubMed ID: 19247653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
    Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of dead time on quantitative
    Desy A; Bouvet GF; Frezza A; Després P; Beauregard JM
    EJNMMI Phys; 2020 May; 7(1):32. PubMed ID: 32415492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twins in spirit part IV - [
    Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
    Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dosimetry procedure for organs-at-risk in
    Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
    Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [
    Blakkisrud J; Peterson AB; Wildermann SJ; Kingkiner G; Wong KK; Wang C; Frey KA; Stokke C; Dewaraja YK
    J Nucl Med; 2024 May; 65(5):753-760. PubMed ID: 38548350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
    Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
    J Nucl Med; 2024 Jun; 65(6):923-930. PubMed ID: 38637144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Reichman K; Haslerud T; Ahmadzadehfar H; Biersack HJ; Nagarajah J; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):505-10. PubMed ID: 24196919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.